Farnborough – October 12, 2026 -- AerCap Holdings N.V. (NYSE: AER) placed a direct order for 15 Boeing 787-9 Dreamliners, taking its fleet of 787 aircraft to approximately 140. The lessor announced the order at the 2026 Farnborough International Air Show.

AerCap schedules deliveries of the 15 aircraft through 2033

The aircraft will be delivered through 2033, giving the lessor a long-dated widebody pipeline. AerCap selected GE Aerospace's GEnx-1B engines to power all 15 jets.

Order includes substitution rights to the larger 787-10

The agreement lets AerCap switch from the 787-9 to the larger 787-10 variant. The company said the option gives it flexibility as it works to meet the changing needs of its customers.

Dublin – October 12, 2026 -- AerCap Holdings N.V. raised its full-year 2026 adjusted earnings per share guidance to approximately $16.80 after reporting second-quarter net income of $726 million, or $4.59 per share. Adjusted net income reached $811 million, or $5.14 per share. The guidance excludes any additional gains on sale for the rest of the year.

AerCap sells $1.4 billion of assets at a 20% unlevered gain margin

The lessor booked a net gain on sale of $223 million on 38 owned assets sold for $1.4 billion. A year earlier it recorded $57 million of gains on 18 assets sold for $374 million. The second-quarter sales equate to 1.7x book value on an equity basis.

Return on equity was 16% for the quarter, or 18% on an adjusted basis. Operating cash flow totaled $1.5 billion.

DUBLIN – October 12, 2026 -- AerCap Holdings N.V. (NYSE: AER) has filed its interim financial report for the quarter ended June 30, 2026, with the U.S. Securities and Exchange Commission, including unaudited condensed consolidated financial statements and notes.

AerCap submits the second-quarter filing on Form 6-K

The report was filed as a Form 6-K. It is available in the Investors section of AerCap's website and on the SEC's website. The announcement itself contained no revenue, earnings or fleet figures; those details sit in the filing.

AerCap lists sanctions, tariffs and rates among the risks to its results

The company's forward-looking statements name the continued impact of the Ukraine conflict as a risk, including sanctions imposed by the United States, the European Union, the United Kingdom and other countries. They also cite hostilities in the Middle East and any escalation of them.

Dublin – October 12, 2026 -- AerCap Holdings N.V. (NYSE: AER) has delivered its 100th Boeing 787 from its direct orderbook with Boeing, a 787-9 placed on lease with Grupo Aeroméxico, which marks the airline's 25th Dreamliner.

AerCap's tenth 787 lease to Aeroméxico doubles as a program milestone

The aircraft is the tenth Boeing 787 that AerCap has leased to Aeroméxico. AerCap describes itself as the world's largest owner of 787s, with the largest 787 order book of any lessor at approximately 140 aircraft owned and on order.

Dublin – October 12, 2026 -- AerCap Funding Designated Activity Company, a wholly-owned subsidiary of AerCap Holdings N.V., has priced $1.5 billion of senior notes split evenly between a 2030 and a 2033 maturity.

AerCap Funding splits the $1.5 billion offering into two $750 million tranches

The 5.500% Senior Notes due 2030 and the 5.875% Senior Notes due 2033 each carry a principal amount of $750 million. The 2033 tranche pays a coupon 0.375 percentage points higher than the 2030 tranche in exchange for three additional years of maturity.

AerCap Holdings and certain other subsidiaries will guarantee the notes fully and unconditionally on a senior unsecured basis.

Dublin – October 12, 2026 -- AerCap Holdings N.V. (NYSE: AER) completed 204 asset transactions in the third quarter of 2026 and returned about $783 million to shareholders through a share repurchase of 5.3 million shares at an average price of $147.12.

AerCap signs 85 leases across aircraft, engines and helicopters

The lessor signed 85 lease agreements in the quarter: 16 widebody aircraft, 45 narrowbody aircraft, 13 engines and 11 helicopters. It also signed financing transactions worth approximately $900 million.

AerCap buys 32 aircraft, led by 20 Boeing 737 MAX jets

AerCap completed 34 purchases covering 32 aircraft and 2 helicopters. The aircraft bought for its owned portfolio were 20 Boeing 737 MAX, 8 Airbus A320neo Family, 2 Boeing 787-9s and 2 Embraer E195-E2s.

Dublin – October 12, 2026 -- AerCap Holdings N.V. (NYSE: AER) will publish its third quarter 2026 financial results before U.S. markets open on Wednesday, October 28, 2026, and discuss them on a conference call at 8:30 a.m. Eastern Time the same day.

AerCap will post the earnings release and call slides on its investor site at the same time

The earnings press release will go live in the Investors section of the company's website before the U.S. market open. The presentation slides for the call will be posted simultaneously, so investors and analysts will have the figures and the slide deck before the call begins.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV), ending a dual listing it says no longer justifies its cost. The company will keep its primary listing on Nasdaq (XRTX) and its Frankfurt listing (ANU).

XORTX, a late-stage clinical pharmaceutical company developing therapies for gout and progressive kidney disease, will announce the timing of the delisting in a separate press release.

XORTX cites duplicate fees and regulatory complexity as reasons for leaving the TSXV

The company said a comprehensive evaluation concluded that the TSXV listing does not justify its costs and administrative requirements. It also said the different regulatory environments create challenges.

XORTX expects the delisting to deliver four outcomes:

Calgary – October 12, 2026 -- XORTX Therapeutics (NASDAQ: XRTX | TSXV: XRTX) has appointed Mika Grasso, 28, as co-CEO responsible for finance and public markets, and says it aims to advance its lead gout program, XRx-026, toward marketing approval over the next 18 months.

The company says the appointment follows a recent financing and growing investor interest. It is now restructuring its corporate and issuer status, re-initiating drug development programs and preparing regulatory filings for XRx-026. Risk disclosures in the release also refer to a voluntary delisting that may not be completed on the anticipated timeline, or at all.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) has appointed Depesh Narotam, a financial services executive with more than 20 years of experience, to its board as an independent director effective July 27, 2026.

Board determines Narotam meets Nasdaq and Canadian independence standards

The board determined that Narotam, 43, is independent under applicable Nasdaq listing standards and Canadian securities laws. He also joins the board's Compensation, Governance and Nominating Committee.

Narotam is a resident of British Columbia, Canada.